Michael Cherny
Stock Analyst at Leerink Partners
(3.48)
# 950
Out of 4,734 analysts
130
Total ratings
55.91%
Success rate
2.14%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACCD Accolade | Downgrades: Market Perform | n/a | $6.88 | - | 8 | Jan 8, 2025 | |
| MCK McKesson | Maintains: Buy | $680 → $650 | $586.08 | +10.91% | 11 | Jan 6, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $228.00 | +22.81% | 2 | Jan 6, 2025 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $135 → $174 | $152.65 | +13.99% | 2 | Jan 6, 2025 | |
| CAH Cardinal Health | Upgrades: Buy | $132 → $145 | $127.83 | +13.43% | 10 | Jan 6, 2025 | |
| HSIC Henry Schein | Upgrades: Buy | $69 → $84 | $74.19 | +13.22% | 2 | Jan 6, 2025 | |
| PDCO Patterson Companies | Downgrades: Market Perform | $29 → $31 | $30.95 | +1.29% | 22 | Dec 11, 2024 | |
| IQV IQVIA Holdings | Reiterates: Outperform | $260 → $248 | $205.69 | +20.57% | 2 | Nov 19, 2024 | |
| ICLR ICON Public Limited Company | Reiterates: Outperform | $270 → $255 | $205.07 | +24.35% | 3 | Nov 19, 2024 | |
| PGNY Progyny | Maintains: Buy | $22 → $21 | $21.48 | -2.23% | 9 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.96 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $16 → $23 | $20.55 | +11.92% | 10 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $29.81 | -16.14% | 9 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $245.07 | +12.21% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $77 | $53.15 | +44.87% | 10 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.57 | +872.76% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.37 | +93.49% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $243.99 | +6.56% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $22.09 | +1.86% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.71 | +69.85% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $32 | $55.52 | -42.36% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $12.61 | +50.67% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $9.50 | +78.95% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $15.06 | +248.61% | 2 | Jan 5, 2022 |
Accolade
Jan 8, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.88
Upside: -
McKesson
Jan 6, 2025
Maintains: Buy
Price Target: $680 → $650
Current: $586.08
Upside: +10.91%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $228.00
Upside: +22.81%
Quest Diagnostics
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $152.65
Upside: +13.99%
Cardinal Health
Jan 6, 2025
Upgrades: Buy
Price Target: $132 → $145
Current: $127.83
Upside: +13.43%
Henry Schein
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $74.19
Upside: +13.22%
Patterson Companies
Dec 11, 2024
Downgrades: Market Perform
Price Target: $29 → $31
Current: $30.95
Upside: +1.29%
IQVIA Holdings
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $205.69
Upside: +20.57%
ICON Public Limited Company
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $205.07
Upside: +24.35%
Progyny
Nov 13, 2024
Maintains: Buy
Price Target: $22 → $21
Current: $21.48
Upside: -2.23%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $18.96
Upside: -
Oct 31, 2024
Upgrades: Market Perform
Price Target: $16 → $23
Current: $20.55
Upside: +11.92%
Oct 21, 2024
Maintains: Buy
Price Target: $23 → $25
Current: $29.81
Upside: -16.14%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $245.07
Upside: +12.21%
May 2, 2024
Maintains: Buy
Price Target: $95 → $77
Current: $53.15
Upside: +44.87%
Apr 22, 2024
Initiates: Outperform
Price Target: $25
Current: $2.57
Upside: +872.76%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.37
Upside: +93.49%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $243.99
Upside: +6.56%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $22.09
Upside: +1.86%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.71
Upside: +69.85%
Feb 26, 2024
Initiates: Market Perform
Price Target: $32
Current: $55.52
Upside: -42.36%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $12.61
Upside: +50.67%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $9.50
Upside: +78.95%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $15.06
Upside: +248.61%